Serina Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SER research report →
Price Chart
About the company
Serina Therapeutics, Inc. , a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease.
- CEO
- Steven A. Ledger
- IPO
- 2018
- Employees
- 16
- HQ
- Huntsville, AL, US
Get TickerSpark's AI analysis on SER
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $39.74M
- P/E
- -1.41
- PEG
- 0.03
- P/S
- 0.00
- P/B
- 2.32
- EV/EBITDA
- -0.90
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -222.42%
- ROIC
- -116.37%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-24,022,000
- Net Income
- $-19,182,000-72.2%
- EPS
- $-1.91-26.5%
- OCF Growth
- -4.8%
- FCF Growth
- -4.6%
- 52W High
- $7.92
- 52W Low
- $1.22
- 50D MA
- $2.14
- 200D MA
- $2.38
- Beta
- 0.03
- RSI (14)
- 61
- Avg Volume
- 85.47K
No earnings-call transcripts are available for SER yet.
- Free Float
- 13.3%
- Shares Outstanding
- 15.00M
- Float Shares
- 1.99M
of shares held by institutions
22 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 180.01K | 0 |
Held by 18 ETFs
Biggest fund positions in SER by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 22, 26 | Simon Farrell | other | 30,500 |
| Jul 22, 26 | Simon Farrell | other | 0 |
| Jul 7, 26 | Brannan Stephen K. | buy | 1,000 |
| Jun 17, 26 | Venkatesan Jay | other | 224,152 |
| Jun 17, 26 | Venkatesan Jay | other | 15,250 |
| May 22, 26 | Venkatesan Jay | buy | 589 |
| Jun 17, 26 | Venkatesan Jay | other | 96,525 |
| Jun 17, 26 | Bailey Gregory | other | 6,666,667 |
| Jun 17, 26 | Bailey Gregory | other | 3,333,333 |
| Jun 17, 26 | Bailey Gregory | other | 1,770,805 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SER coverage
Recent articles, reports, and earnings notes.
No research on SER yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SER report →Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
globenewswire.com · Aug 13
Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
globenewswire.com · Jul 24
Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson's Disease
globenewswire.com · Jul 23
Serina Therapeutics Appoints Farrell Simon to its Board of Directors
globenewswire.com · Jul 22
Serina Therapeutics Appoints Farrell Simon to its Board of Directors
globenewswire.com · Jul 22
Seres Therapeutics' SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study
marketbeat.com · Jul 10
Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
globenewswire.com · Jul 9
Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease
globenewswire.com · Jul 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.